Literature DB >> 31768373

Association of Myoinositol Transporters with Schizophrenia and Bipolar Disorder: Evidence from Human and Animal Studies.

Marquis P Vawter1, Abdul Rezzak Hamzeh2, Edgar Muradyan3, Olivier Civelli3,4,5, Geoffrey W Abbott6, Amal Alachkar3,4.   

Abstract

Evidence from animal and human studies has linked myo-inositol (MI) with the pathophysiology and/or treatment of psychiatric disorders such as schizophrenia and bipolar disorder. However, there is still controversy surrounding the definitive role of MI in these disorders. Given that brain MI is differentially regulated by three transporters - SMIT1, SMIT2 and/or HMIT (encoded by the genes: SLC5A3, SLC5A11, and SLC2A13, respectively) - we used available datasets to describe the distribution in mouse and human brain of the different MI transporters and to examine changes in mRNA expression of these transporters in patients with schizophrenia and bipolar disorder. We found a differential distribution of the mRNA of each of the three MI transporters in both human and mouse brain regions. Interestingly, while individual neurons express SMIT1 and HMIT, non-neuronal cells express SMIT2, thus partially accounting for different uptake levels of MI and concordance to downstream second messenger signaling pathways. We also found that the expression of MI transporters is significantly changed in schizophrenia and bipolar disorder in a diagnostic-, brain region- and subtype-specific manner. We then examined the effects of germline deletion in mice of Slc5a3 on behavioral phenotypes related to schizophrenia and bipolar disorder. This gene deletion produces behavioral deficits that mirror some specific symptoms of schizophrenia and bipolar disorder. Finally, chronic administration of MI was able to reverse particular, but not all, behavioral deficits in Slc5a3 knockout mice; MI itself induced some behavioral deficits. Our data support a strong correlation between the expression of MI transporters and schizophrenia and bipolar disorder, and suggest that brain region-specific aberration of one or more of these transporters determines the partial behavioral phenotypes and/or symptomatic pattern of these disorders.
Copyright © 2019 by S. Karger AG, Basel.

Entities:  

Keywords:  Bipolar disorder; Human brain; Myoinositol transporters; Schizophrenia; Slc5a3 knockout mice

Year:  2019        PMID: 31768373      PMCID: PMC6873027          DOI: 10.1159/000501125

Source DB:  PubMed          Journal:  Mol Neuropsychiatry        ISSN: 2296-9179


  51 in total

1.  Genome-wide atlas of gene expression in the adult mouse brain.

Authors:  Ed S Lein; Michael J Hawrylycz; Nancy Ao; Mikael Ayres; Amy Bensinger; Amy Bernard; Andrew F Boe; Mark S Boguski; Kevin S Brockway; Emi J Byrnes; Lin Chen; Li Chen; Tsuey-Ming Chen; Mei Chi Chin; Jimmy Chong; Brian E Crook; Aneta Czaplinska; Chinh N Dang; Suvro Datta; Nick R Dee; Aimee L Desaki; Tsega Desta; Ellen Diep; Tim A Dolbeare; Matthew J Donelan; Hong-Wei Dong; Jennifer G Dougherty; Ben J Duncan; Amanda J Ebbert; Gregor Eichele; Lili K Estin; Casey Faber; Benjamin A Facer; Rick Fields; Shanna R Fischer; Tim P Fliss; Cliff Frensley; Sabrina N Gates; Katie J Glattfelder; Kevin R Halverson; Matthew R Hart; John G Hohmann; Maureen P Howell; Darren P Jeung; Rebecca A Johnson; Patrick T Karr; Reena Kawal; Jolene M Kidney; Rachel H Knapik; Chihchau L Kuan; James H Lake; Annabel R Laramee; Kirk D Larsen; Christopher Lau; Tracy A Lemon; Agnes J Liang; Ying Liu; Lon T Luong; Jesse Michaels; Judith J Morgan; Rebecca J Morgan; Marty T Mortrud; Nerick F Mosqueda; Lydia L Ng; Randy Ng; Geralyn J Orta; Caroline C Overly; Tu H Pak; Sheana E Parry; Sayan D Pathak; Owen C Pearson; Ralph B Puchalski; Zackery L Riley; Hannah R Rockett; Stephen A Rowland; Joshua J Royall; Marcos J Ruiz; Nadia R Sarno; Katherine Schaffnit; Nadiya V Shapovalova; Taz Sivisay; Clifford R Slaughterbeck; Simon C Smith; Kimberly A Smith; Bryan I Smith; Andy J Sodt; Nick N Stewart; Kenda-Ruth Stumpf; Susan M Sunkin; Madhavi Sutram; Angelene Tam; Carey D Teemer; Christina Thaller; Carol L Thompson; Lee R Varnam; Axel Visel; Ray M Whitlock; Paul E Wohnoutka; Crissa K Wolkey; Victoria Y Wong; Matthew Wood; Murat B Yaylaoglu; Rob C Young; Brian L Youngstrom; Xu Feng Yuan; Bin Zhang; Theresa A Zwingman; Allan R Jones
Journal:  Nature       Date:  2006-12-06       Impact factor: 49.962

2.  Inositol treatment of autism.

Authors:  J Levine; A Aviram; A Holan; A Ring; Y Barak; R H Belmaker
Journal:  J Neural Transm (Vienna)       Date:  1997       Impact factor: 3.575

3.  Temporal dissociation between lithium-induced changes in frontal lobe myo-inositol and clinical response in manic-depressive illness.

Authors:  G J Moore; J M Bebchuk; J K Parrish; M W Faulk; C L Arfken; J Strahl-Bevacqua; H K Manji
Journal:  Am J Psychiatry       Date:  1999-12       Impact factor: 18.112

4.  Inositol treatment of obsessive-compulsive disorder.

Authors:  M Fux; J Levine; A Aviv; R H Belmaker
Journal:  Am J Psychiatry       Date:  1996-09       Impact factor: 18.112

5.  Inositol Depletion Induced by Acute Treatment of the Bipolar Disorder Drug Valproate Increases Levels of Phytosphingosine.

Authors:  Shyamalagauri Jadhav; Sarah Russo; L Ashley Cowart; Miriam L Greenberg
Journal:  J Biol Chem       Date:  2017-01-18       Impact factor: 5.157

6.  Sodium-myo-inositol co-transporter (SMIT-1) mRNA is increased in neutrophils of patients with bipolar 1 disorder and down-regulated under treatment with mood stabilizers.

Authors:  Frank Willmroth; Tobias Drieling; Ulrich Lamla; Michael Marcushen; Hans-Jörg Wark; Dietrich van Calker
Journal:  Int J Neuropsychopharmacol       Date:  2006-01-18       Impact factor: 5.176

7.  Double-blind, controlled, crossover trial of inositol versus fluvoxamine for the treatment of panic disorder.

Authors:  A Palatnik; K Frolov; M Fux; J Benjamin
Journal:  J Clin Psychopharmacol       Date:  2001-06       Impact factor: 3.153

8.  Assessment of murine startle reactivity, prepulse inhibition, and habituation.

Authors:  Mark A Geyer; Stephanie C Dulawa
Journal:  Curr Protoc Neurosci       Date:  2003-11

9.  The human osmoregulatory Na+/myo-inositol cotransporter gene (SLC5A3): molecular cloning and localization to chromosome 21.

Authors:  G T Berry; J J Mallee; H M Kwon; J S Rim; W R Mulla; M Muenke; N B Spinner
Journal:  Genomics       Date:  1995-01-20       Impact factor: 5.736

10.  The Human Cell Atlas.

Authors:  Aviv Regev; Sarah A Teichmann; Eric S Lander; Ido Amit; Christophe Benoist; Ewan Birney; Bernd Bodenmiller; Peter Campbell; Piero Carninci; Menna Clatworthy; Hans Clevers; Bart Deplancke; Ian Dunham; James Eberwine; Roland Eils; Wolfgang Enard; Andrew Farmer; Lars Fugger; Berthold Göttgens; Nir Hacohen; Muzlifah Haniffa; Martin Hemberg; Seung Kim; Paul Klenerman; Arnold Kriegstein; Ed Lein; Sten Linnarsson; Emma Lundberg; Joakim Lundeberg; Partha Majumder; John C Marioni; Miriam Merad; Musa Mhlanga; Martijn Nawijn; Mihai Netea; Garry Nolan; Dana Pe'er; Anthony Phillipakis; Chris P Ponting; Stephen Quake; Wolf Reik; Orit Rozenblatt-Rosen; Joshua Sanes; Rahul Satija; Ton N Schumacher; Alex Shalek; Ehud Shapiro; Padmanee Sharma; Jay W Shin; Oliver Stegle; Michael Stratton; Michael J T Stubbington; Fabian J Theis; Matthias Uhlen; Alexander van Oudenaarden; Allon Wagner; Fiona Watt; Jonathan Weissman; Barbara Wold; Ramnik Xavier; Nir Yosef
Journal:  Elife       Date:  2017-12-05       Impact factor: 8.140

View more
  2 in total

1.  The sodium/myo-inositol co-transporter SLC5A3 promotes non-small cell lung cancer cell growth.

Authors:  Zihan Cui; Chuanyong Mu; Zhichao Wu; Shu Pan; Zewen Cheng; Zhi-Qing Zhang; Jun Zhao; Chun Xu
Journal:  Cell Death Dis       Date:  2022-06-27       Impact factor: 9.685

Review 2.  Sodium-coupled glucose transport, the SLC5 family, and therapeutically relevant inhibitors: from molecular discovery to clinical application.

Authors:  Gergely Gyimesi; Jonai Pujol-Giménez; Yoshikatsu Kanai; Matthias A Hediger
Journal:  Pflugers Arch       Date:  2020-08-07       Impact factor: 3.657

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.